← Back to Search

Monoclonal Antibodies

Pharmacokinetics of certolizumab pegol for Epidural Block (CHERISH Trial)

Phase 1
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to delivery (duration of pregnancy, up to 40 weeks)
Awards & highlights

CHERISH Trial Summary

This trial will study the effects of certolizumab pegol, a drug used to treat chronic inflammatory diseases, during pregnancy.

Eligible Conditions
  • Epidural Block
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Crohn's Disease
  • Ankylosing Spondylitis
  • Plaque Psoriasis

CHERISH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to delivery (duration of pregnancy, up to 40 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to delivery (duration of pregnancy, up to 40 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Predose and postdose plasma certolizumab pegol (CZP) concentrations in women during pregnancy, relative to postpartum
Secondary outcome measures
Adverse events from time of informed consent through Safety Follow-up (SFU)
Plasma levels of anti-certolizumab pegol (CZP) antibodies throughout the study period
Pregnancy outcome

CHERISH Trial Design

1Treatment groups
Experimental Treatment
Group I: Pharmacokinetics SamplingExperimental Treatment1 Intervention
This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label. From all study participants blood samples will be drawn for pharmacokinetics during the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pharmacokinetics of certolizumab pegol
2020
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
101 Previous Clinical Trials
21,395 Total Patients Enrolled
UCB Biopharma S.P.R.L.Lead Sponsor
71 Previous Clinical Trials
11,782 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273 (UCB)
203 Previous Clinical Trials
44,340 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Federal Drug Administration issued a stamp of approval for Pharmacokinetics of certolizumab pegol?

"Our team's evaluation of certolizumab pegol's safety was a 1, as the medication is currently in Phase 1 clinical trials and has limited backing for both efficacy and safety."

Answered by AI

Have previous experiments assessed the Pharmacokinetics of certolizumab pegol?

"Currently, 17 studies are actively researching the Pharmacokinetics of certolizumab pegol, with 4 trials in Phase 3. Shanghai is hosting many of these investigations but there are an additional 238 locations running trails for this pharmacological topic."

Answered by AI

To what extent is this experiment being conducted on a global scale?

"At present, there are 4 medical centres taking part in this study. These facilities can be found in Oklahoma City, Houston and Minneapolis as well as one other city. To reduce the demands of travel for patients involved in this trial, it is advisable to choose a centre that is close by."

Answered by AI

What therapeutic applications does certolizumab pegol typically serve?

"Certolizumab pegol is commonly used as a pharmacological agent to manage the symptoms of severe psoriatic arthritis, Crohn's disease, and other forms of rheumatoid inflammation."

Answered by AI

What is the total sample size of this investigation?

"Regrettably, no more patients can be accepted into this trial as the last update was posted on September 15th 2022. However, 839 studies looking at rheumatoid arthritis and 17 related to pharmacokinetics of certolizumab pegol are actively recruiting participants if you're interested in other clinical trials."

Answered by AI

Is enrollment still open for this research initiative?

"Per the official documents hosted on clinicaltrials.gov, recruitment for this medical study has already concluded. Initially posted in June 2020 and last updated September 2022, 856 other trials are currently open to new recruits instead."

Answered by AI
~5 spots leftby Mar 2025